risperidone and Insulin Resistance studies

Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.

Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.

Research Excerpts

Excerpt	Relevance	Reference
"Rapid weight gain with risperidone treatment may promote the cascade of biochemical indices associated with insulin resistance and metabolic syndrome."	9.22	Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder. ( Aman, MG; Arnold, LE; Boorin, SJ; Caprio, S; Challa, SA; Deng, Y; Dziura, J; Jeon, S; McCracken, JT; McDougle, CJ; Nicol, G; Scahill, L; Vitiello, B, 2016)
"Patients with an acute psychotic episode underwent HOMA testing for insulin sensitivity (IS) prior to and after 3 weeks of treatment with olanzapine (n = 7) or risperidone (n = 7)."	9.16	The differential effect of risperidone and olanzapine on insulin sensitivity after 3 weeks of treatment: a HOMA pilot study. ( Deuschle, M; Kopf, D; Paslakis, G; Rüsse, S; Thome, J, 2012)
"Small, but statistically significant, decrements in insulin sensitivity were observed in olanzapine- and risperidone-treated patients at 1 of 2 insulin doses tested."	9.15	Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder. ( Campbell, GM; Forrester, TD; Hardy, TA; Henry, RR; Kryzhanovskaya, LA; Marks, DM; Mudaliar, S, 2011)
"Eight patients with psychotic disorders (ages 11-17) who had started risperidone (mean: 1."	9.14	Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment. ( Maayan, LA; Vakhrusheva, J, 2010)
" Olanzapine-treated patients showed a significantly greater increase than risperidone-treated patients in a fasting measure of insulin resistance (P = ."	9.14	Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. ( Cornwell, J; Davis, JM; Hu, Q; Kelly, E; Khan, A; Lindenmayer, JP; Smith, RC; Vaidhyanathaswamy, S; Viviano, TF, 2009)
"The primary objective of this study was to evaluate insulin sensitivity in healthy subjects treated with olanzapine or risperidone."	9.10	Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. ( Breier, A; Carlson, C; Cavazzoni, P; Chinnapongse, S; Dananberg, J; Davis, T; Henry, RR; Mudaliar, S; Mukhopadhyay, N; Ray, A; Sowell, M, 2003)
"Our findings support the primary role of schizophrenia in metabolic abnormalities and risperidone appear beneficial when administered earlier."	8.31	Effects of Early Risperidone Treatment on Metabolic Parameters in Socially Isolated Rats-Implication of Antipsychotic Intervention across Developmental Stages of Schizophrenia. ( Hsieh, PS; Lin, CC; Liu, YP; Tzeng, NS; Yang, YY, 2023)
"Risperidone use in children and adolescents is associated with the development of metabolic disorders including increased accumulation of body fat, dyslipidemia, and glucose and insulin metabolism dysregulation."	7.96	Exercise intervention for preventing risperidone-induced dyslipidemia and gluco-metabolic disorders in female juvenile rats. ( Deng, C; Han, M; Sylvester, E; Yi, W, 2020)
"The purpose of this study was to explore the association of genetic polymorphism of genes related to pharmacokinetics or pharmacodynamics with insulin resistance in children and adolescents with autism spectrum disorder (ASD) and treated with risperidone."	7.88	Pharmacogenetics of Risperidone-Induced Insulin Resistance in Children and Adolescents with Autism Spectrum Disorder. ( Chamkrachangpada, B; Hongkaew, Y; Limsila, P; Ngamsamut, N; Nuntamool, N; Puangpetch, A; Srisawasdi, P; Sukasem, C; Vanwong, N, 2018)
" The goal of this study was to understand the relationship between clozapine and risperidone with glucose and lipid metabolism and dietary fat intake in patients with schizophrenia."	7.76	Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone. ( Borba, CP; Cather, C; Copeland, PM; Evins, AE; Fan, X; Freudenreich, O; Goff, DC; Henderson, DC; Sharma, B, 2010)
"Olanzapine and risperidone may impair glucose tolerance due in part to increased insulin resistance."	7.75	Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine. ( Furukori, H; Kaneko, S; Nakagami, T; Saito, M; Sato, Y; Yasui-Furukori, N, 2009)
"We studied a sample of schizophrenia out-patients to test the hypotheses that serum homocysteine concentrations would correlate positively with measures of glucose metabolism."	7.73	Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia. ( Baer, L; Borba, CP; Cather, C; Copeland, PM; Eden Evins, A; Freudenreich, O; Goff, DC; Henderson, DC; Nguyen, DD, 2006)
" In conclusion, long-term administration of risperidone may exacerbate diabetes syndrome, nonalcoholic fatty liver disease, and kidney injury."	5.62	Risperidone Exacerbates Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Renal Impairment in Obese Mice. ( Chang, CC; Chang, GR; Chou, LS; Hou, PH; Hsiao, LW; Liao, HJ; Lin, TC; Mao, FC; Tsai, HP; Wu, CF; Yang, WC, 2021)
"Adverse changes in adiposity and insulin sensitivity were observed during 12 weeks of antipsychotic treatment in youths, with the greatest fat increases on olanzapine."	5.27	Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial. ( Flavin, KS; Newcomer, JW; Nicol, GE; Patterson, BW; Schechtman, KB; Schweiger, JA; Yingling, MD, 2018)
"Rapid weight gain with risperidone treatment may promote the cascade of biochemical indices associated with insulin resistance and metabolic syndrome."	5.22	Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder. ( Aman, MG; Arnold, LE; Boorin, SJ; Caprio, S; Challa, SA; Deng, Y; Dziura, J; Jeon, S; McCracken, JT; McDougle, CJ; Nicol, G; Scahill, L; Vitiello, B, 2016)
"Patients with an acute psychotic episode underwent HOMA testing for insulin sensitivity (IS) prior to and after 3 weeks of treatment with olanzapine (n = 7) or risperidone (n = 7)."	5.16	The differential effect of risperidone and olanzapine on insulin sensitivity after 3 weeks of treatment: a HOMA pilot study. ( Deuschle, M; Kopf, D; Paslakis, G; Rüsse, S; Thome, J, 2012)
"Small, but statistically significant, decrements in insulin sensitivity were observed in olanzapine- and risperidone-treated patients at 1 of 2 insulin doses tested."	5.15	Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder. ( Campbell, GM; Forrester, TD; Hardy, TA; Henry, RR; Kryzhanovskaya, LA; Marks, DM; Mudaliar, S, 2011)
"Eight patients with psychotic disorders (ages 11-17) who had started risperidone (mean: 1."	5.14	Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment. ( Maayan, LA; Vakhrusheva, J, 2010)
" Olanzapine-treated patients showed a significantly greater increase than risperidone-treated patients in a fasting measure of insulin resistance (P = ."	5.14	Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. ( Cornwell, J; Davis, JM; Hu, Q; Kelly, E; Khan, A; Lindenmayer, JP; Smith, RC; Vaidhyanathaswamy, S; Viviano, TF, 2009)
"We performed a 6-month, randomized, double-blind study to evaluate the effects of risperidone and olanzapine in patients with schizophrenia."	5.13	Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia. ( Ader, M; Bergman, RN; Berry, SA; Garvey, WT; Gharabawi, G; Greenspan, A; Mahmoud, R; Mao, L; Morein, J; Musselman, DL; Nemeroff, CB; Phillips, LS; Zhu, Y, 2008)
" Planned assessments included body mass index (BMI), waist-to-hip ratio, fasting glucose, insulin, C-peptide, insulin resistance index (IRI), cholesterol, and triglyceride."	5.12	Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. ( Guo, WB; Guo, XF; Liu, ZN; Tang, JS; Wu, RR; Zhai, JG; Zhao, JP, 2006)
"The primary objective of this study was to evaluate insulin sensitivity in healthy subjects treated with olanzapine or risperidone."	5.10	Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. ( Breier, A; Carlson, C; Cavazzoni, P; Chinnapongse, S; Dananberg, J; Davis, T; Henry, RR; Mudaliar, S; Mukhopadhyay, N; Ray, A; Sowell, M, 2003)
"Our findings support the primary role of schizophrenia in metabolic abnormalities and risperidone appear beneficial when administered earlier."	4.31	Effects of Early Risperidone Treatment on Metabolic Parameters in Socially Isolated Rats-Implication of Antipsychotic Intervention across Developmental Stages of Schizophrenia. ( Hsieh, PS; Lin, CC; Liu, YP; Tzeng, NS; Yang, YY, 2023)
"Risperidone use in children and adolescents is associated with the development of metabolic disorders including increased accumulation of body fat, dyslipidemia, and glucose and insulin metabolism dysregulation."	3.96	Exercise intervention for preventing risperidone-induced dyslipidemia and gluco-metabolic disorders in female juvenile rats. ( Deng, C; Han, M; Sylvester, E; Yi, W, 2020)
"The purpose of this study was to explore the association of genetic polymorphism of genes related to pharmacokinetics or pharmacodynamics with insulin resistance in children and adolescents with autism spectrum disorder (ASD) and treated with risperidone."	3.88	Pharmacogenetics of Risperidone-Induced Insulin Resistance in Children and Adolescents with Autism Spectrum Disorder. ( Chamkrachangpada, B; Hongkaew, Y; Limsila, P; Ngamsamut, N; Nuntamool, N; Puangpetch, A; Srisawasdi, P; Sukasem, C; Vanwong, N, 2018)
"Risperidone treatment disturbed glucose homeostasis and endocrine regulation (particularly leptin) in children and adolescents with ASDs, in a dose- and duration-dependent manner, being suggestive of leptin and insulin resistance mechanisms."	3.85	Impact of risperidone on leptin and insulin in children and adolescents with autistic spectrum disorders. ( Hongkaew, Y; Intachak, B; Kroll, MH; Limsila, P; Ngamsamut, N; Puangpetch, A; Srisawasdi, P; Sukasem, C; Vanavanan, S; Vanwong, N, 2017)
" After 4-week administration, clozapine (10mg/kg/d) and risperidone (1mg/kg/d) both caused glucose intolerance and insulin resistance in VD deficient rats, but not in rats with sufficient VD status."	3.81	Vitamin D deficiency exacerbates atypical antipsychotic-induced metabolic side effects in rats: involvement of the INSIG/SREBP pathway. ( Cai, H; Dang, R; Guo, R; He, X; Jiang, P; Li, H; Liu, Y; Wu, Y; Xu, P; Zhang, L; Zhu, W, 2015)
" The purpose of this study was to compare glucose homeostasis, insulin sensitivity, insulin secretion, and overall β-cell function in risperidone-treated, quetiapine-treated, and SGA-naive youth with mental illness."	3.80	Quetiapine treatment in youth is associated with decreased insulin secretion. ( Chanoine, JP; Davidson, J; Devlin, AM; Lynn, FC; Ngai, YF; Nguyen, D; Panagiotopoulos, C; Sabatini, P, 2014)
"The study population comprised 113 Japanese inpatients with schizophrenia who were treated with olanzapine, risperidone, or quetiapine, and 123 healthy control (CONT) volunteers."	3.78	Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia. ( Fukui, N; Ono, S; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J, 2012)
"Compared with weight measured concurrently, the rate of weight gain in risperidone-treated children accounts for an equal or larger share of the variance in certain cardiometabolic outcomes (eg, HDL cholesterol [ΔR(2) = 8% vs ΔR(2) = 11%] and high-sensitivity C-reactive protein [ΔR(2) = 5% vs ΔR(2) = 9%]) and may serve as a treatment target."	3.78	Rate of weight gain and cardiometabolic abnormalities in children and adolescents. ( Burns, TL; Calarge, CA; Fiedorowicz, JG; Haynes, WG; Xie, D, 2012)
"In subproject Ι, 45 patients receiving the 2nd generation antipsychotics risperidone, clozapine or olanzapine were compared regarding prolactin (PRL), body mass index (BMI), insulin, homeostasis model assessment of insulin resistance (HOMA-IR) and blood lipids."	3.77	Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses. ( Berinder, K; Hulting, AL; Melkersson, K, 2011)
" The goal of this study was to understand the relationship between clozapine and risperidone with glucose and lipid metabolism and dietary fat intake in patients with schizophrenia."	3.76	Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone. ( Borba, CP; Cather, C; Copeland, PM; Evins, AE; Fan, X; Freudenreich, O; Goff, DC; Henderson, DC; Sharma, B, 2010)
"Olanzapine and risperidone may impair glucose tolerance due in part to increased insulin resistance."	3.75	Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine. ( Furukori, H; Kaneko, S; Nakagami, T; Saito, M; Sato, Y; Yasui-Furukori, N, 2009)
" Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis."	3.73	Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. ( Allison, DB; Anderson, EJ; Borba, CP; Cagliero, E; Copeland, PM; Daley, TB; Evins, AE; Goff, DC; Hayden, D; Henderson, DC; Schoenfeld, D; Weber, MT, 2005)
" We examined the effects of atypical antipsychotics olanzapine (OLZ) and risperidone (RIS) versus placebo on adiposity, insulin sensitivity (S(I)), and pancreatic beta-cell compensation."	3.73	Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. ( Ader, M; Bergman, RN; Catalano, KJ; Hucking, K; Ionut, V; Kabir, M; Kim, SP; Richey, JM, 2005)
"We studied a sample of schizophrenia out-patients to test the hypotheses that serum homocysteine concentrations would correlate positively with measures of glucose metabolism."	3.73	Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia. ( Baer, L; Borba, CP; Cather, C; Copeland, PM; Eden Evins, A; Freudenreich, O; Goff, DC; Henderson, DC; Nguyen, DD, 2006)
" Role of ghrelin (RIA), resistin and TNF-alpha (ELISA) in weight gain and insulin resistance (fasting plasma insulin, HOMA, ELISA) was studied in Hungarian psychiatryic patients (n=60) treated with SGA (clozapine, olanzapine, risperidone, quetiapine, 15 each)."	3.73	[Possible connection between ghrelin, resistin and TNF-alpha levels and the metabolic syndrome caused by atypical antipsychotics]. ( Birkás Kováts, D; Cseh, K; Faludi, G; Palik, E, 2005)
" To investigate the possible mechanisms of antipsychotic-induced metabolic effects, we studied the impact of chronic administration of a typical antipsychotic drug (haloperidol) and an atypical antipsychotic (risperidone) to male rats on food intake, body weight, adiposity, and the circulating concentrations of hormones and metabolites that can influence energy homeostasis."	3.73	Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats. ( Dedova, I; Duffy, L; Herzog, H; Karl, T; Lee, NJ; Lin, EJ; Matsumoto, I; O'brien, E; Sainsbury, A; Slack, K, 2006)
"Weight gain was positively correlated with changes in insulin levels, insulin resistance index and triglyceride levels."	2.74	Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population. ( Amado, JA; Berja, A; Crespo-Facorro, B; Garcia-Unzueta, MT; Martinez-Garcia, O; Mata, I; Pelayo-Teran, JM; Perez-Iglesias, R; Vazquez-Barquero, JL, 2009)
" In conclusion, long-term administration of risperidone may exacerbate diabetes syndrome, nonalcoholic fatty liver disease, and kidney injury."	1.62	Risperidone Exacerbates Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Renal Impairment in Obese Mice. ( Chang, CC; Chang, GR; Chou, LS; Hou, PH; Hsiao, LW; Liao, HJ; Lin, TC; Mao, FC; Tsai, HP; Wu, CF; Yang, WC, 2021)
"Insulin resistance is the result of the multiple effects of the antipsychotics, among which most common are: increased body mass and direct involvement of the antipsychotics in the glucose metabolism."	1.34	Second generation antipsychotics and risk of diabetes type II--comparison between olanzapine and risperidone. ( Degmecić, D; Filaković, P; Koić, O; Laufer, D; Pozgain, I; Radanović-Grgurić, L, 2007)

Research

Studies (44)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

Change in DEXA % Body Fat

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	19 (43.18)	29.6817
2010's	21 (47.73)	24.3611
2020's	4 (9.09)	2.80

Authors	Studies
Tzeng, NS	1
Yang, YY	1
Lin, CC	1
Hsieh, PS	1
Liu, YP	1
Sylvester, E	1
Yi, W	1
Han, M	1
Deng, C	1
Tsai, HP	1
Hou, PH	1
Mao, FC	1
Chang, CC	1
Yang, WC	1
Wu, CF	1
Liao, HJ	1
Lin, TC	1
Chou, LS	1
Hsiao, LW	1
Chang, GR	1
Boyda, HN	2
Procyshyn, RM	2
Tse, L	2
Yuen, JWY	1
Honer, WG	1
Barr, AM	2
Sukasem, C	2
Vanwong, N	2
Srisawasdi, P	2
Ngamsamut, N	2
Nuntamool, N	1
Hongkaew, Y	2
Puangpetch, A	2
Chamkrachangpada, B	1
Limsila, P	2
Nicol, GE	1
Yingling, MD	1
Flavin, KS	1
Schweiger, JA	1
Patterson, BW	1
Schechtman, KB	1
Newcomer, JW	1
Aboul-Fotouh, S	1
Elgayar, N	1
Ngai, YF	1
Sabatini, P	1
Nguyen, D	1
Davidson, J	1
Chanoine, JP	1
Devlin, AM	1
Lynn, FC	1
Panagiotopoulos, C	1
Bonaccorso, S	1
Sodhi, M	1
Li, J	1
Bobo, WV	1
Chen, Y	1
Tumuklu, M	1
Theleritis, C	1
Jayathilake, K	1
Meltzer, HY	1
Dang, R	1
Jiang, P	1
Cai, H	1
Li, H	1
Guo, R	1
Wu, Y	1
Zhang, L	1
Zhu, W	1
He, X	1
Liu, Y	1
Xu, P	1
Scahill, L	1
Jeon, S	1
Boorin, SJ	1
McDougle, CJ	1
Aman, MG	1
Dziura, J	1
McCracken, JT	1
Caprio, S	1
Arnold, LE	1
Nicol, G	1
Deng, Y	1
Challa, SA	1
Vitiello, B	1
Vanavanan, S	1
Intachak, B	1
Kroll, MH	1
Perez-Iglesias, R	1
Mata, I	1
Pelayo-Teran, JM	1
Amado, JA	1
Garcia-Unzueta, MT	1
Berja, A	1
Martinez-Garcia, O	1
Vazquez-Barquero, JL	1
Crespo-Facorro, B	1
Yasui-Furukori, N	1
Sato, Y	1
Furukori, H	1
Saito, M	1
Nakagami, T	1
Kaneko, S	1
Smith, RC	1
Lindenmayer, JP	1
Davis, JM	1
Kelly, E	1
Viviano, TF	1
Cornwell, J	1
Hu, Q	1
Khan, A	1
Vaidhyanathaswamy, S	1
Park, S	2
Hong, SM	1
Ahn, IL	1
Kim, DS	1
Kim, SH	1
Maayan, LA	1
Vakhrusheva, J	1
Henderson, DC	3
Sharma, B	1
Fan, X	1
Copeland, PM	3
Borba, CP	3
Freudenreich, O	2
Cather, C	2
Evins, AE	2
Goff, DC	3
Wong, D	1
Wu, TK	1
Pang, CC	1
Albaugh, VL	1
Vary, TC	1
Ilkayeva, O	1
Wenner, BR	1
Maresca, KP	1
Joyal, JL	1
Breazeale, S	1
Elich, TD	1
Lang, CH	1
Lynch, CJ	1
Hardy, TA	1
Henry, RR	2
Forrester, TD	1
Kryzhanovskaya, LA	1
Campbell, GM	1
Marks, DM	1
Mudaliar, S	2
Wampers, M	1
Hanssens, L	1
van Winkel, R	1
Heald, A	1
Collette, J	1
Peuskens, J	1
Reginster, JY	1
Scheen, A	1
De Hert, M	1
Adeneye, AA	1
Agbaje, EO	1
Olagunju, JA	1
Melkersson, K	1
Berinder, K	1
Hulting, AL	1
Paslakis, G	1
Deuschle, M	1
Thome, J	1
Rüsse, S	1
Kopf, D	1
Sugai, T	1
Suzuki, Y	1
Fukui, N	1
Ono, S	1
Watanabe, J	1
Tsuneyama, N	1
Someya, T	1
Calarge, CA	1
Xie, D	1
Fiedorowicz, JG	1
Burns, TL	1
Haynes, WG	1
Sowell, M	1
Mukhopadhyay, N	1
Cavazzoni, P	1
Carlson, C	1
Chinnapongse, S	1
Ray, A	1
Davis, T	1
Breier, A	1
Dananberg, J	1
Schwenkreis, P	1
Assion, HJ	1
Cagliero, E	1
Hayden, D	1
Weber, MT	1
Anderson, EJ	1
Allison, DB	1
Daley, TB	1
Schoenfeld, D	1
Ader, M	2
Kim, SP	1
Catalano, KJ	1
Ionut, V	1
Hucking, K	1
Richey, JM	1
Kabir, M	1
Bergman, RN	2
Bakos, CD	1
Berecz, R	1
Degrell, I	1
Filaković, P	2
Laufer, D	2
Radanović-Grgurić, L	2
Koić, O	2
Fijacko, M	1
Durković, M	1
Nguyen, DD	1
Eden Evins, A	1
Baer, L	1
Birkás Kováts, D	1
Palik, E	1
Faludi, G	1
Cseh, K	1
Wu, RR	1
Zhao, JP	1
Liu, ZN	1
Zhai, JG	1
Guo, XF	1
Guo, WB	1
Tang, JS	1
Lin, EJ	1
Lee, NJ	1
Slack, K	1
Karl, T	1
Duffy, L	1
O'brien, E	1
Matsumoto, I	1
Dedova, I	1
Herzog, H	1
Sainsbury, A	1
Baptista, T	1
Martinez, M	1
Lacruz, A	1
Arellano, A	1
Mendoza, S	1
Beaulieu, S	1
Hernández, L	1
Contreras, Q	1
Galeazzi, T	1
Vargas, D	1
Jindal, RD	1
Wooten, J	1
Degmecić, D	1
Pozgain, I	1
Garvey, WT	1
Phillips, LS	1
Nemeroff, CB	1
Gharabawi, G	1
Mahmoud, R	1
Greenspan, A	1
Berry, SA	1
Musselman, DL	1
Morein, J	1
Zhu, Y	1
Mao, L	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Metabolic Effects of Antipsychotics in Children[NCT00205699]	Phase 4	144 participants (Actual)	Interventional	2006-04-30	Completed
Risperidone and Behavioral Therapy in Treatment of Children and Adolescents With Autistic Disorder[NCT00080145]		124 participants (Actual)	Interventional	2004-02-29	Completed
Independent Investigator Grant Study-Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism[NCT00287820]	Phase 4	46 participants (Anticipated)	Interventional	2004-02-29	Completed
A Double-blind, Placebo-controlled, Crossover Study Examining the Acute Effects of Olanzapine on Plasma Leptin, Glucose Tolerance and Free Fatty Acids in Healthy Volunteers[NCT00741026]		15 participants (Actual)	Interventional	2008-08-31	Completed
Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504]	Phase 4	25 participants (Actual)	Interventional	2008-01-31	Completed
Phase 4 Study of the Effects of Pravastatin on Cholesterol Levels, Inflammation and Cognition in Schizophrenia[NCT01082588]	Phase 4	60 participants (Actual)	Interventional	2010-06-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

This study hypothesized that antipsychotic treatment would increase percent total body fat, as measured by whole body dual energy x-ray absorptiometry (DEXA), with larger adverse effects for olanzapine. (NCT00205699)
Timeframe: 12 weeks

Change in Insulin-stimulated Glucose Rate of Appearance (Glucose Ra)

Intervention	percent body fat (Mean)
Risperidone	1.81
Olanzapine	4.12
Aripiprazole	1.66

This study hypothesized that antipsychotic treatment would decrease hepatic insulin sensitivity, as measured by the rate of appearance of glucose (glucose Ra), with larger adverse effects for olanzapine. (NCT00205699)
Timeframe: 12 weeks

Change in Insulin-stimulated Glucose Rate of Disappearance (Glucose Rd)

Intervention	percentage of % change (Mean)
Risperidone	-2.50
Olanzapine	-6.57
Aripiprazole	-3.27

This study hypothesized that antipsychotic treatment would decrease insulin sensitivity at muscle, as measured by the insulin-stimulated rate of disappearance of glucose (glucose Rd), with larger adverse effects for olanzapine. (NCT00205699)
Timeframe: 12 weeks

Change in Insulin-stimulated Glycerol Rate of Appearance (Glycerol Ra)

Intervention	percentage of % change (Mean)
Risperidone	2.30
Olanzapine	-29.34
Aripiprazole	-30.26

This study hypothesized that antipsychotic treatment would decrease insulin sensitivity at adipose tissue, as measured by the insulin-stimulated rate of disappearance of glycerol (glycerol Ra), with larger adverse effects for olanzapine. (NCT00205699)
Timeframe: 12 weeks

Change in MRI-measured Subcutaneous Abdominal Fat

Intervention	percentage of % change (Mean)
Risperidone	-3.65
Olanzapine	-8.29
Aripiprazole	1.70

This study hypothesized that antipsychotic treatment would increase subcutaneous abdominal fat, as measured by abdominal magnetic resonance imaging (MRI), with larger adverse effects for olanzapine. (NCT00205699)
Timeframe: 12 weeks

Change in MRI-measured Visceral Abdominal Fat

Intervention	Change in cm-squared (Mean)
Risperidone	18.21
Olanzapine	34.27
Aripiprazole	15.84

This study hypothesized that antipsychotic treatment would increase visceral abdominal fat, as measured by abdominal magnetic resonance imaging (MRI), with larger adverse effects for olanzapine. (NCT00205699)
Timeframe: 12 weeks

BMI

Body Weight

Diastolic Blood Pressure

HDL Cholesterol

Heart Rate

LDL Cholesterol

Oral Glucose Tolerance

Plasma Free Fatty Acid

Plasma Leptin

Intervention	Change in cm-squared (Mean)
Risperidone	6.85
Olanzapine	10.73
Aripiprazole	12.04

Intervention	kg / m2 (Mean)
Placebo	23.0
Olanzapine	23.0

Intervention	kg (Mean)
Placebo	68.2
Olanzapine	68.9

Intervention	mmHg (Mean)
Placebo	68.3
Olanzapine	69.5

Intervention	mg/dl (Mean)
Placebo	54.2
Olanzapine	48.9

Intervention	beats per minute (Mean)
Placebo	69.9
Olanzapine	67.6

Intervention	mg/dl (Mean)
Placebo	82.7
Olanzapine	81.7

Intervention	min*mg/dl (Mean)
Placebo	2808
Olanzapine	3984

Intervention	mM (Mean)
Placebo	0.38
Olanzapine	0.26

Leptin following placebo or olanzapine treatment (NCT00741026)
Timeframe: 3 Days

Systolic Blood Pressure

Total Cholesterol

Triglycerides

Change in Abdominal Fat (DEXA).

Intervention	ng/ml (Mean)
Placebo	6.8
Olanzapine	8.4

Intervention	mmHg (Mean)
Placebo	113.3
Olanzapine	111.7

Intervention	mg/dl (Mean)
Placebo	156.8
Olanzapine	152.6

Intervention	mg/dl (Mean)
Placebo	88.9
Olanzapine	108.2

A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8

Change in Insulin Resistance as Measured by the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).

Intervention	g (Mean)
Ramelteon	3934.86
Placebo (Sugar Pill)	5120.92

A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8

Change in Waist Circumference

Intervention	HOMA score (Mean)
Ramelteon	2.4
Placebo (Sugar Pill)	2.36

A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8

Change in C-Reactive Protein (CRP) From Baseline to Week 12

Change in LDL-cholesterol Between Baseline and Week 12

Change in MATRICS Neuropsychological Battery Composite Score From Baseline to Week 12

Intervention	cm (Mean)
Ramelteon	106.09
Placebo (Sugar Pill)	108.37

Intervention	mg/L (Mean)
Pravastatin	0.8063
Placebo	-0.5136

Intervention	mg/dl (Mean)
Pravastatin	-25.565
Placebo	-2.913

"The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery measures cognitive functioning within 7 domains: speed of processing, attention/vigilance, working memory (non verbal and verbal), verbal learning, visual learning, reasoning and problem solving and social cognition.~The composite score is calculated by the MATRICS computer program, which equally weights each of the 7 domain scores. The range of composite scores is 20-80. Higher scores indicate higher levels or cognitive functioning, while lower scores indicate lower levels of cognitive functioning." (NCT01082588)
Timeframe: Baseline, week 12

Change in Positive and Negative Syndrome Scale (PANSS) General Score From Baseline to Week 12

Intervention	Scores on a scale (Mean)
Pravastatin	4.0417
Placebo	4.125

This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 15-105. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12

Change in Positive and Negative Syndrome Scale (PANSS) Negative Score From Baseline to Week 12

Intervention	Scores on a scale (Mean)
Pravastatin	-5.625
Placebo	-3.76

This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12

Change in Positive and Negative Syndrome Scale (PANSS) Positive Score From Baseline to Week 12

Intervention	Scores on a scale (Mean)
Pravastatin	-0.83
Placebo	-0.28

Change in Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline to Week 12

Intervention	Scores on a scale (Mean)
Pravastatin	-2.9583
Placebo	-2.44

The Positive and Negative Syndrome Scale (PANSS) is a scale used to rate severity of schizophrenia. All items are summed to calculate the total score. The scale range is 30-210. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12

Article	Year
Atypical antipsychotics and diabetes mellitus. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2004, Volume: 5, Issue:2 Topics: Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus; Dibenzothiazepines; Glucose; Humans; Insul	2004
Metabolic effects of the atypical antipsychotics. Southern medical journal, 2007, Volume: 100, Issue:8 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepine	2007

Article	Year
Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial. JAMA psychiatry, 2018, 08-01, Volume: 75, Issue:8 Topics: Abdominal Fat; Absorptiometry, Photon; Adolescent; Antipsychotic Agents; Aripiprazole; Child; Drug-R	2018
The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia. Bipolar disorders, 2015, Volume: 17, Issue:5 Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Body Mass In	2015
Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, Volume: 55, Issue:5 Topics: Antipsychotic Agents; Autism Spectrum Disorder; Child; Child, Preschool; Female; Humans; Insulin Res	2016
Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population. Schizophrenia research, 2009, Volume: 107, Issue:2-3 Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Cholesterol, H	2009
Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. The Journal of clinical psychiatry, 2009, Volume: 70, Issue:11 Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Chronic Disease;	2009
Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment. Human psychopharmacology, 2010, Volume: 25, Issue:2 Topics: Adolescent; Anthropometry; Antidepressive Agents, Second-Generation; Body Mass Index; Body Size; Bod	2010
Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder. Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:8 Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucos	2011
Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2012, Volume: 22, Issue:1 Topics: Adiponectin; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Female; Humans; Insulin	2012
The differential effect of risperidone and olanzapine on insulin sensitivity after 3 weeks of treatment: a HOMA pilot study. Pharmacopsychiatry, 2012, Volume: 45, Issue:3 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Female; Homeostasis	2012
Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. The Journal of clinical endocrinology and metabolism, 2003, Volume: 88, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Fasting; Fatty Acids, None	2003
Newer antipsychotics and glucose metabolism: a comparison between olanzapine and risperidone. Psychiatria Danubina, 2005, Volume: 17, Issue:1-2 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gluc	2005
Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology, 2006, Volume: 186, Issue:4 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; C-Peptide; Cholesterol	2006
Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia. Schizophrenia research, 2007, Volume: 89, Issue:1-3 Topics: Adult; Antipsychotic Agents; Appetite; Benzodiazepines; Blood Glucose; Chronic Disease; Delayed-Acti	2007
Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia. Journal of psychiatric research, 2008, Volume: 42, Issue:13 Topics: Absorptiometry, Photon; Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Blood Gl	2008

Article	Year
Effects of Early Risperidone Treatment on Metabolic Parameters in Socially Isolated Rats-Implication of Antipsychotic Intervention across Developmental Stages of Schizophrenia. Journal of integrative neuroscience, 2023, Jan-05, Volume: 22, Issue:1 Topics: Animals; Antipsychotic Agents; Body Weight; Insulin Resistance; Insulins; Rats; Risperidone; Schizop	2023
Exercise intervention for preventing risperidone-induced dyslipidemia and gluco-metabolic disorders in female juvenile rats. Pharmacology, biochemistry, and behavior, 2020, Volume: 199 Topics: Animals; Antipsychotic Agents; Blood Glucose; Body Mass Index; Dyslipidemias; Female; Glucose Tolera	2020
Risperidone Exacerbates Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Renal Impairment in Obese Mice. International journal of molecular sciences, 2021, Jan-02, Volume: 22, Issue:1 Topics: Adipocytes; Adiponectin; Alanine Transaminase; Animals; Aspartate Aminotransferases; Body Weight; Ca	2021
A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models. PloS one, 2021, Volume: 16, Issue:1 Topics: Animals; Antipsychotic Agents; Female; Glucose Clamp Technique; Glucose Tolerance Test; Insulin Resi	2021
Pharmacogenetics of Risperidone-Induced Insulin Resistance in Children and Adolescents with Autism Spectrum Disorder. Basic & clinical pharmacology & toxicology, 2018, Volume: 123, Issue:1 Topics: Adolescent; Adult; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B; Autism Spect	2018
Atypical antipsychotics such as risperidone, but not paliperidone, worsen vascular endothelial function via upregulation of adhesion molecules VCAM-1, ICAM-1, and E-selectin in diabetic rats. Canadian journal of physiology and pharmacology, 2013, Volume: 91, Issue:12 Topics: Animals; Antipsychotic Agents; Aorta; Blood Pressure; Cell Adhesion Molecules; Chemokine CCL2; Cytok	2013
Quetiapine treatment in youth is associated with decreased insulin secretion. Journal of clinical psychopharmacology, 2014, Volume: 34, Issue:3 Topics: Adolescent; Animals; Antipsychotic Agents; Blood Glucose; Body Mass Index; Child; Cross-Sectional St	2014
Vitamin D deficiency exacerbates atypical antipsychotic-induced metabolic side effects in rats: involvement of the INSIG/SREBP pathway. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2015, Volume: 25, Issue:8 Topics: Animals; Antipsychotic Agents; Body Weight; Clozapine; Disease Models, Animal; Eating; Glucose Intol	2015
Impact of risperidone on leptin and insulin in children and adolescents with autistic spectrum disorders. Clinical biochemistry, 2017, Volume: 50, Issue:12 Topics: Adiponectin; Adolescent; Antipsychotic Agents; Autistic Disorder; Blood Glucose; C-Reactive Protein;	2017
Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine. The Journal of clinical psychiatry, 2009, Volume: 70, Issue:1 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gluc	2009
Olanzapine, not resperidone, exacerbates beta-cell function and mass in ovariectomized diabetic rats and estrogen replacement reverses them. Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:7 Topics: Adipose Tissue; Animals; Antipsychotic Agents; Benzodiazepines; Blotting, Western; Cell Separation;	2010
Estrogen replacement reverses olanzapine-induced weight gain and hepatic insulin resistance in ovariectomized diabetic rats. Neuropsychobiology, 2010, Volume: 61, Issue:3 Topics: Adipose Tissue; Animals; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 2; Eating; E	2010
Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2010, Volume: 22, Issue:1 Topics: Adult; Analysis of Variance; Antipsychotic Agents; Blood Glucose; Clozapine; Cross-Sectional Studies	2010
A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Progress in neuro-psychopharmacology & biological psychiatry, 2010, Aug-16, Volume: 34, Issue:6 Topics: Analysis of Variance; Animals; Antipsychotic Agents; Blood Glucose; Clozapine; Dose-Response Relatio	2010
Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents. Schizophrenia bulletin, 2012, Volume: 38, Issue:1 Topics: Animals; Antipsychotic Agents; Benzodiazepines; Carnitine; Clozapine; Energy Metabolism; Fatty Acids	2012
Metformin: an effective attenuator of risperidone-induced insulin resistance hyperglycemia and dyslipidemia in rats. Indian journal of experimental biology, 2011, Volume: 49, Issue:5 Topics: Animals; Antipsychotic Agents; Blood Glucose; Disease Models, Animal; Dyslipidemias; Glyburide; Huma	2011
Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses. Neuro endocrinology letters, 2011, Volume: 32, Issue:4 Topics: Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Clozapine; Female; Gluco	2011
Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia. Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:3 Topics: Adiponectin; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cross-Sectiona	2012
Rate of weight gain and cardiometabolic abnormalities in children and adolescents. The Journal of pediatrics, 2012, Volume: 161, Issue:6 Topics: Adolescent; Antipsychotic Agents; Biomarkers; Blood Pressure; Body Mass Index; Child; Female; Humans	2012
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Archives of general psychiatry, 2005, Volume: 62, Issue:1 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Clozapine	2005
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Archives of general psychiatry, 2005, Volume: 62, Issue:1 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Clozapine	2005
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Archives of general psychiatry, 2005, Volume: 62, Issue:1 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Clozapine	2005
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Archives of general psychiatry, 2005, Volume: 62, Issue:1 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Clozapine	2005
Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes, 2005, Volume: 54, Issue:3 Topics: Adipose Tissue; Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Dietary Fats; Dogs; Ins	2005
[Effect of atypical antipsychotics on metabolism]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2004, Volume: 6, Issue:2 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol, HDL; Glucose Tolerance Tes	2004
Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia. Acta psychiatrica Scandinavica, 2006, Volume: 113, Issue:2 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Blood Pressure; Chronic Disease; Clozap	2006
[Possible connection between ghrelin, resistin and TNF-alpha levels and the metabolic syndrome caused by atypical antipsychotics]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2005, Volume: 7, Issue:3 Topics: Antipsychotic Agents; Benzodiazepines; Carbohydrate Metabolism; Case-Control Studies; Clozapine; Dib	2005
Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats. Neuropharmacology, 2006, Volume: 51, Issue:7-8 Topics: Adipose Tissue; Animals; Antipsychotic Agents; Appetite; Body Weight; Corticosterone; Diabetes Melli	2006
Acute insulin response and beta-cell compensation in normal subjects treated with olanzapine or risperidone for 2 weeks: response to Hardy et al. Diabetes care, 2007, Volume: 30, Issue:7 Topics: Animals; Antipsychotic Agents; Benzodiazepines; Dogs; Dose-Response Relationship, Drug; Humans; Insu	2007
Second generation antipsychotics and risk of diabetes type II--comparison between olanzapine and risperidone. Collegium antropologicum, 2007, Volume: 31, Issue:4 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Diabetes Mellitus, Type 2; Female; Gl	2007
[Schizophrenia and diabetes alliance. No increased insulin resistance due to risperidone]. MMW Fortschritte der Medizin, 2001, May-28, Volume: 143 Suppl 2 Topics: Body Weight; Diabetes Mellitus, Type 2; Female; Humans; Insulin Resistance; Male; Risperidone; Schiz	2001

risperidone and Insulin Resistance